Can I Take Ashwagandha With PT-141 (Bremelanotide)?

What PT-141 (Bremelanotide) Actually Does

PT-141, sold as Vyleesi, is a synthetic peptide that activates melanocortin receptors, specifically MC3R and MC4R, in the central nervous system. This central action increases sexual desire independent of vascular mechanisms, which is how it differs from phosphodiesterase-5 inhibitors like sildenafil.

The FDA approved bremelanotide in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Off-label, prescribers use it for men with low libido and, less commonly, erectile dysfunction where psychological or central-drive components are involved.

Mechanism at the Melanocortin System

Bremelanotide binds MC3R and MC4R with high affinity. MC4R activation in the hypothalamus drives appetitive sexual behavior. The drug does not significantly affect genital blood flow directly and produces its effect within roughly 45 minutes of subcutaneous injection.

Pharmacokinetics Relevant to Combination Use

Bremelanotide is metabolized primarily by hydrolysis, not by cytochrome P450 enzymes [2]. That single fact is the most important pharmacokinetic point for this article: because CYP enzymes are not meaningfully involved in its clearance, ashwagandha constituents that mildly inhibit CYP3A4 or CYP2C9 are unlikely to alter bremelanotide plasma levels in a clinically meaningful way.

Peak plasma concentration (Cmax) occurs at approximately 1 hour post-injection. Half-life is roughly 2.7 hours. The drug is largely cleared within 12 hours.

What Ashwagandha Does Hormonally

Ashwagandha (Withania somnifera) is an adaptogenic root extract used in Ayurvedic medicine for centuries. Modern clinical trials test root extracts standardized to 2.5% to 5% withanolides, with common commercial doses of 300 mg to 600 mg twice daily.

Its hormonal effects touch three systems that are also relevant to sexual function: the hypothalamic-pituitary-adrenal (HPA) axis, the gonadal axis, and, to a lesser degree, thyroid regulation.

Effects on Cortisol and the HPA Axis

The most replicated effect of ashwagandha is cortisol reduction. A randomized, double-blind, placebo-controlled trial published in Medicine (N=64) found that 240 mg/day of ashwagandha extract for 60 days reduced serum cortisol by 23% compared to placebo (P<0.001) [3].

A second trial (N=58) using 300 mg twice daily for 8 weeks reported a 27.9% reduction in serum cortisol alongside significant improvements in self-reported stress scores [4].

Sustained high cortisol suppresses gonadotropin-releasing hormone (GnRH), which in turn dampens LH, FSH, and sex hormone production. By lowering cortisol, ashwagandha may restore some of that gonadal signal.

Effects on Testosterone

A 2019 pilot trial (N=43 overweight men, 8 weeks, 600 mg/day ashwagandha) showed a statistically significant increase in testosterone of 14.7% vs. 2.9% in placebo (P<0.05) [5]. A separate study in male infertility (N=46) reported serum testosterone increases of approximately 17% after 90 days of supplementation [6].

These gains are modest. They are also observed almost exclusively in men with baseline stress, overweight status, or subfertility. Data in healthy eugonadal men or in women are substantially weaker.

Effects on Thyroid Hormones

Several small studies suggest ashwagandha root extract may raise T3 and T4 modestly. One 8-week randomized controlled trial (N=50 with subclinical hypothyroidism) found significant increases in T3 and T4 and a reduction in TSH compared to placebo [7]. The effect is not large enough to treat overt hypothyroidism, but it is clinically relevant for people with thyroid disease or those on levothyroxine.

Bremelanotide, by contrast, has no documented thyroid effect in its FDA label or in published pharmacological data. Thyroid monitoring in anyone combining these agents is still reasonable if they have a pre-existing thyroid condition.

The Interaction Between Ashwagandha and Bremelanotide: Is It Pharmacokinetic or Pharmacodynamic?

The interaction, if it exists at all, is pharmacodynamic. Meaning the two substances do not meaningfully alter each other's absorption, distribution, metabolism, or excretion. Instead, they influence overlapping biological systems that together affect sexual function and hormonal balance.

The HealthRX clinical team developed a three-domain framework for categorizing how adaptogens overlap with peptide-based sexual function drugs:

Domain 1: Hormonal axis overlap. Does the supplement alter cortisol, testosterone, estrogen, or thyroid hormones in a direction that either compounds or counteracts the peptide's mechanism? For ashwagandha plus bremelanotide, both agents push toward improved sexual-desire signaling. Ashwagandha reduces cortisol (which may improve gonadal hormone milieu); bremelanotide directly activates central desire circuitry. These effects are additive in direction, not antagonistic.

Domain 2: Metabolic / enzymatic pathway conflict. Do they share CYP enzymes, transporters (P-gp, OATP), or plasma protein binding sites in a way that alters drug levels? For this pair: no. Bremelanotide's hydrolytic clearance and ashwagandha's primary withanolide metabolism do not converge at the same enzymatic bottleneck.

Domain 3: Autonomic / cardiovascular overlap. Bremelanotide causes transient blood pressure increases: a mean increase of 6 mmHg systolic and 3 mmHg diastolic peaking around 4 hours post-dose and resolving within 12 hours [2]. Ashwagandha, in most trials, has a mild blood-pressure-lowering effect. The net cardiovascular interaction is likely neutral or slightly mitigating, but this has not been tested in a controlled head-to-head study.

Is the Combination Safe?

For most healthy adults without thyroid disease, cardiovascular disease, or adrenal disorders, combining ashwagandha and bremelanotide carries low documented risk. The absence of pharmacokinetic conflict is meaningful. The pharmacodynamic overlap is generally directionally aligned, meaning both agents support sexual desire through complementary rather than opposing pathways.

"low documented risk" is not the same as "no risk." Several populations deserve more careful evaluation.

Who Should Be More Cautious

People with thyroid disorders. Ashwagandha may raise T3 and T4 [7]. If you take levothyroxine or have hyperthyroidism, adding ashwagandha could shift your thyroid status. Bremelanotide does not add thyroid risk directly, but the combined hormonal environment in someone with thyroid disease warrants closer monitoring.

People with adrenal insufficiency or who use corticosteroids. Ashwagandha's cortisol-lowering effect might exacerbate relative cortisol deficiency in people with HPA axis compromise. This has not been studied in combination with bremelanotide specifically.

People on anticoagulants or sedatives. Ashwagandha may mildly potentiate sedatives and has some theoretical interaction with warfarin, though clinical evidence is sparse [8]. Bremelanotide does not list relevant drug interactions with these agents.

Pregnant women. Bremelanotide is contraindicated in pregnancy. Ashwagandha has demonstrated abortifacient potential in animal studies and should also be avoided [9]. This is the one population where neither agent is appropriate.

What the FDA Label Says

The FDA prescribing information for Vyleesi explicitly lists no herb-drug interactions in its drug interactions section. The label states that bremelanotide "is primarily metabolized by enzymatic hydrolysis" and identifies naltrexone as the only clinically meaningful interaction, because naltrexone occupies opioid receptors that modulate the same hypothalamic circuitry targeted by bremelanotide [2].

The American College of Obstetricians and Gynecologists (ACOG) notes in its 2019 clinical guidance on female sexual dysfunction that "treatment of HSDD should account for comorbid conditions and the patient's complete medication and supplement list" [10].

Dosing, Timing, and Practical Guidance

Timing the two agents relative to each other does not require a strict separation window because the interaction is pharmacodynamic rather than pharmacokinetic.

Bremelanotide Dosing Schedule

The standard Vyleesi dose is 1.75 mg subcutaneous injection administered approximately 45 minutes before anticipated sexual activity. The drug should not be used more than once in 24 hours and more than 8 times per month per the FDA label [2]. Because it peaks around 60 minutes and clears within 12 hours, its active window is narrow and predictable.

Ashwagandha Dosing Schedule

Most well-designed trials use 300 mg to 600 mg of root extract standardized to withanolides, taken once or twice daily with food. The cortisol-lowering effect accumulates over weeks rather than occurring acutely, which means ashwagandha is a daily, steady-state supplement rather than an on-demand drug.

There is no pharmacological reason to hold ashwagandha on days you use bremelanotide. The 45-minute bremelanotide injection window is unaffected by ashwagandha co-ingestion.

Suggested Monitoring Protocol

Before combining the two, obtain baseline labs including:

• Serum cortisol (morning, 8 a.m.)
• Total testosterone (and free testosterone if available)
• TSH, free T3, free T4 (especially if you have any thyroid history)
• Blood pressure at rest

Recheck these values at 8 weeks if continuing ashwagandha daily. Adjust or discontinue ashwagandha if TSH drops below normal range or if cortisol falls to a level inconsistent with normal HPA function.

What the Evidence Does Not Tell Us

No randomized controlled trial has tested ashwagandha and bremelanotide together. That gap is not unique to this pairing. Most supplement-drug interaction data rely on in vitro enzyme inhibition studies, case reports, or mechanistic inference rather than head-to-head clinical trials.

The Natural Medicines database (Therapeutic Research Center) rates the ashwagandha-bremelanotide combination as having "insufficient reliable information available" for a formal interaction classification. That rating reflects absence of evidence, not evidence of absence.

Because bremelanotide works centrally through melanocortin receptors and ashwagandha works primarily through HPA-axis modulation and partial gonadotropin support, the two pathways are genuinely distinct at a molecular level. Neither agent relies on the same receptor family for its primary effect.

What Animal Data Suggests

Withanolide A and withaferin A, two key bioactive compounds in ashwagandha, have been shown in rodent models to reduce corticosterone (the rat equivalent of cortisol) and to increase mounting behavior and testosterone levels in stressed animals [9]. These findings support, at a mechanistic level, the idea that ashwagandha might complement bremelanotide's central desire-promoting effects by reducing a key hormonal brake on sexual function. Whether that translates to additive clinical benefit in humans has not been tested.

Clinical Scenarios Where This Combination Is Often Discussed

Scenario 1: Premenopausal Woman With HSDD and High Stress

A 38-year-old woman is prescribed Vyleesi for HSDD. She also takes ashwagandha 300 mg twice daily for work-related stress. Her TSH is normal. In this case, the combination is reasonable. The ashwagandha may help reduce the chronic cortisol burden that is suppressing her libido, while bremelanotide addresses the acute, on-demand, central desire deficit. No dose adjustment of either agent is indicated. A TSH recheck at 8 weeks is appropriate.

Scenario 2: Man Using PT-141 Off-Label for Low Libido

A 44-year-old man uses compounded PT-141 injections off-label. He has been taking ashwagandha 600 mg/day for three months and has noted a modest increase in energy and libido. His testosterone at baseline was 410 ng/dL, now 467 ng/dL. This hormonal shift is within normal range and does not represent a safety concern. The off-label PT-141 use, however, requires a supervising physician regardless of the supplement picture.

Scenario 3: Person With Subclinical Hypothyroidism

A 52-year-old perimenopausal woman has a TSH of 4.9 mIU/L (mildly elevated, not yet on medication). She wants to try ashwagandha for stress and PT-141 for low libido. Given that ashwagandha may raise T3 and T4 and suppress TSH in people with subclinical hypothyroidism [7], this scenario warrants a thyroid panel before starting ashwagandha and a repeat panel at 6 to 8 weeks. Bremelanotide does not compound the thyroid variable here.

Key Takeaways for Clinicians and Patients

The question of whether ashwagandha and PT-141 can be combined comes down to three practical answers:

1. No pharmacokinetic interaction exists. Bremelanotide's hydrolytic clearance does not involve CYP enzymes that ashwagandha inhibits in vitro.

2. A pharmacodynamic overlap exists, and it runs in the same direction. Both agents broadly support sexual function and hormonal balance, with no mechanistic antagonism identified.

3. Thyroid and cortisol monitoring matters. Ashwagandha's hormonal effects are real, if modest, and anyone with a pre-existing endocrine condition needs labs before and during use.

The FDA label for Vyleesi does not list herbal supplements as contraindications. Physicians prescribing bremelanotide should ask patients about ashwagandha use, document it, and check a baseline thyroid panel if the patient has any thyroid history or takes thyroid medication.

If you are already taking both agents without physician supervision, the most important immediate step is to get a morning cortisol, TSH, and testosterone drawn so your provider has a baseline before continuing.